Nivolumab in Renal Cell Carcinoma

Dr. Overman on the Impact of Nivolumab in mCRC

Nivolumab (Opdivo) Approved in Japan for the Treatment of Advanced Melanoma

Dr Awad on the FDA Approval of Perioperative Nivolumab for Resectable NSCLC

Subcutaneous Versus IV Nivolumab for Kidney Cancer

Dr. Weber on Nivolumab in the Adjuvant Setting for Melanoma

Dr. Schwartz on the Benefit of Dose Reduced Nivolumab/Ipilimumab in Metastatic Sarcomas

Dr. Heymach on the Significance of Nivolumab for Lung Cancer

Dr. Levy on Impact of Nivolumab, Pembrolizumab Approvals in NSCLC